RXRX RECURSION PHARMACEUTICALS CLASS A
Health Care · Russell 2000
Next earnings: not announced yet
What 10 analyst firms say about RECURSION PHARMACEUTICALS CLASS A: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
7 rated views · 10 analyst/firm records · 10 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Fewer than 4 price targets in the last 6 months (3)
- Russell 2000 · Safest consensus · 6MNot scored · Fewer than 4 price targets in the last 6 months (3)
Recent analyst activity · last 90 days
Our tracked history has 3 reports on RXRX from 3 analyst firms in the last 90 days (10 firms in the past year).
Comparing each firm's latest target with its previous one: 1 raised its price target and 1 left it unchanged.
No firm's latest available rating differs from its previous one.
Latest observed target change: Morgan Stanley raised its target from $5.50 (set 14 May 2026) to $5.90 on 16 Oct 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Bank of America Securities | Michael Ryskin | Hold | 25 Feb 2026 | 6.00 USD |
| Jefferies | Dennis Ding | Hold | 26 Feb 2026 | 4.00 USD |
| JPMorgan | Priyanka Grover | Buy | 30 Apr 2026 | 10.00 USD |
| KeyBanc Capital Markets | Scott Schoenhaus | Buy | 6 May 2026 | 10.00 USD |
| Morgan Stanley | Sean Laaman | — | 16 Oct 2026 | 5.90 USD |
| Needham | Gil Blum | Buy | 19 Oct 2026 | 8.00 USD |
| TD Cowen | Brendan Smith | Hold | 15 Jun 2026 | — |
| UBS | Unnamed analyst | — | 17 Dec 2025 | 11.00 USD |
| Weiss Ratings | Unnamed analyst | — | 15 Oct 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | 5.00 USD |
Partial coverage · checked 6 Nov (6 Nov 2026, 02:53 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.